biotech firms expanding glp-1 use beyond diabetes and obesity 2025 Market Size, Scope, Forecast Report 2026 to 2035 GLP-1 Receptor Agonist Market Valued
Description
The MHRA has updated its GLP-1 guidance due to a risk of the rare occurence of NAION among semaglutide patients
From Trend to Research Topic You mayRead Article
Key Benefits & Features
Provide antioxidant support & contribute to overall well-being
Prioritize strength training and adequate protein to preserve metabolism, stay stro
Background Over the coming years, the market for anti-obesity medicines (AOMs), including glucagon-like peptide-1 (GLP-1) receptor agonists, is projected to grow more rapidly in ex-US markets than in the US
